Conference
name:
2nd International conference on pathology
Short
name:
Pathology 2019
Venue :
Paris,France| July 5-6,2019
URL:: https://bit.ly/2GS09CI
Mismatch repair deficiency represents a biomarker of immuno response and
a phenotypic feature of kill syndrome-associated mucosal cancers. employing a
targeted next-generation sequencing assay, we have a tendency to diagonized
molecular symptoms of mate repair deficiency, specifically insertion and
deletion mutations in mononucleotide repeats, and established thresholds for
the amount of such mutations to classify mucosal cancers as mismatch repair
deficient, proficient, or indeterminate. Sequencing classification was compared
to the loss of MLH1, MSH2, MSH6, or PMS2 expression by assay.
a complete of 259 mucosal cancers were classified by sequencing as
mismatch repair deficient (n = 48, 19%), practiced (n = 199, 77%), or
indeterminate (n = 12, 5%). Sequencing findings were concordant with loss of
expression of a minimum of one mismatch repair macromolecule in forty seven of
forty eight (98%) cases classified as deficient and preserved expression of all
four proteins in a hundred ninety of 199 (95%) cases classified as good. Of the
twelve cases classified as indeterminate, seven (58%) incontestable mismatch
repair macromolecule loss.
Overall, targeted next-generation sequencing exhibited a high rate of
concordance with assay for mate repair deficiency; however, sequencing was
indeterminate during a few cases and discovered a false negative rate of fifty.
though we suggest implementation of a mismatch repair deficiency formula for
laboratories activity next-generation sequencing cancer panels, assay remains
an economical screening methodology for mismatch repair deficiency in
endometrial carcinoma.
Contact
KRISTIE NOVA
Program Director | PATHOLOGY 2019
Phone: (44) 20 3769 1755
No comments:
Post a Comment